Phase II Study of Docetaxel and Celecoxib, a Cyclooxygenase-2 Inhibitor, in Elderly or Poor Performance Status (PS2) Patients with Advanced Non-small Cell Lung Cancer

INTRODUCTION: The utility of two-drug chemotherapy regimens in elderly or performance status (PS 2) patients with advanced non-small cell lung cancer (NSCLC) remains to be established. Preclinical studies suggested that celecoxib, a Cyclooxygenase-2 inhibitor, has antitumor activity in NSCLC and can...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Gadgeel, Shirish M., Wozniak, Antoinette, Ruckdeschel, John C., Heilbrun, Lance K., Venkatramanamoorthy, Raghu, Chaplen, Ruth A., Kraut, Michael J., Kalemkerian, Gregory P.
Formato: Artigo
Idioma:Inglês
Publicado em: 2008
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3859308/
https://ncbi.nlm.nih.gov/pubmed/18978565
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/JTO.0b013e31818b194e
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados